Pregnancy as an Early Cardiovascular Moment: Peripartum Cardiovascular Health

• Published in: Circulation research Vol. 132; no. 12; pp. 1584 - 1606
• Main Authors: Khan, Sadiya S., Cameron, Natalie A., Lindley, Kathryn J.
• Format: Journal Article
• Language: English
• Published: United States Lippincott Williams & Wilkins 09.06.2023
• Subjects: Adult; Cardiovascular Diseases - diagnosis; Cardiovascular Diseases - epidemiology; Female; Humans; Hypertension; Infant, Newborn; Peripartum Period; Pregnancy; Pregnancy Outcome; Premature Birth - prevention & control; risk factors; cardiovascular diseases; cardiovascular health; pregnancy; women
• ISSN: 0009-7330; 1524-4571
• DOI: 10.1161/CIRCRESAHA.123.322001

Pregnancy is commonly referred to as a window into future CVH (cardiovascular health). During pregnancy, physiological adaptations occur to promote the optimal growth and development of the fetus. However, in approximately 20% of pregnant individuals, these perturbations result in cardiovascular and metabolic complications, which include hypertensive disorders of pregnancy, gestational diabetes, preterm birth, and small-for-gestational age infant. The biological processes that lead to adverse pregnancy outcomes begin before pregnancy with higher risk of adverse pregnancy outcomes observed among those with poor prepregnancy CVH. Individuals who experience adverse pregnancy outcomes are also at higher risk of subsequent development of cardiovascular disease, which is largely explained by the interim development of traditional risk factors, such as hypertension and diabetes. Therefore, the peripartum period, which includes the period before (prepregnancy), during, and after pregnancy (postpartum), represents an early cardiovascular moment or window of opportunity when CVH should be measured, monitored, and modified (if needed). However, it remains unclear whether adverse pregnancy outcomes reflect latent risk for cardiovascular disease that is unmasked in pregnancy or if adverse pregnancy outcomes are themselves an independent and causal risk factor for future cardiovascular disease. Understanding the pathophysiologic mechanisms and pathways linking prepregnancy CVH, adverse pregnancy outcomes, and cardiovascular disease are necessary to develop strategies tailored for each stage in the peripartum period. Emerging evidence suggests the utility of subclinical cardiovascular disease screening with biomarkers (eg, natriuretic peptides) or imaging (eg, computed tomography for coronary artery calcium or echocardiography for adverse cardiac remodeling) to identify risk-enriched postpartum populations and target for more intensive strategies with health behavior interventions or pharmacological treatments. However, evidence-based guidelines focused on adults with a history of adverse pregnancy outcomes are needed to prioritize the prevention of cardiovascular disease during the reproductive years and beyond.